NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

The presentations included new data from studies of NovaBay's Aganocide compounds, which indicated that NovaBay's Aganocide compounds are highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi in preclinical testing.

Dr. Ron Najafi, chairman and CEO of NovaBay, said, "These presentations clearly illustrated the potency and versatility of our lead Aganocide compounds that are currently in four Phase 2 human trials. In our 1st poster we demonstrated their ability to inhibit harmful bacteria in biofilm inside urinary catheters; our 2nd poster confirmed their dual antimicrobial/anticoagulant properties; in our 3rd poster we displayed antiviral activity against the H1N1 influenza virus in cell culture studies; and in our 4th poster our research indicated that these compounds are effective in killing pathogens such as P. aeruginosa and S. aureus without harming dermal and ocular tissues."

NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical programs and is currently in four Phase 2 clinical trials, including for: impetigo, a highly contagious skin infection; urinary catheter bacterial biofilm blockage, encrustation and associated infection; conjunctivitis, or pink eye infection; and acne.

The posters and their conclusions were as follows:

Efficacy of NVC-422, a Novel Derivative of N-Chlorotaurine, in Controlling Crystalline Proteus mirabilis Biofilm Formation on Urinary Catheters:

Dr. Dmitri Debabov et al. investigated the potential use of NVC-422 as an irrigation solution to resolve catheter biofilm blockage and encrustation caused by P. mirabilis, a Gram-negative bacterium. Results indicated that a 0.2% irrigation solution of NVC-422 kept a urinary Foley catheter unblocked for 144 hours and no biofilm was apparent. The researchers concluded that a bladder irrigation solution using NVC-422 could manage catheter biofilm blockage and encrustation if used on a regular basis. Based on this report and NovaBay's previously reported successful Phase 1 and 2a human trials, an expanded Phase 2b trial is planned for this unmet medical need affecting paraplegic, quadriplegic, stroke, and multiple sclerosis patients.

http://www.novabaypharma.com/media/Novel_compound_inhibit_biofilm_urinary_catherers.shtml

Anticoagulant Effects of N-Chlorotaurine and the Analogs N-Monochloro-2,2-Dimethyltaurine and N,N-Dichloro-2,2-Dimethyltaurine:

Professor Markus Nagl, MD et al. evaluated the effect of NCT, NVC-612 and NVC-422 on blood coagulation pathways. The aim was to evaluate the compounds' potential roles as anticoagulants, which, in addition to their known antimicrobial activity, would make them candidates for catheter lock solutions. At the evaluated concentrations, the compounds exhibited both antimicrobial and anticoagulant properties. Further investigation into this novel anticoagulant property is underway at NovaBay and the Medical University of Innsbruck in Austria to develop potential therapeutic applications.

http://www.novabaypharma.com/media/Compounds_double_as_antimicrobials_anticoagulants.shtml

In Vitro Activity of N-Chlorotaurine (NCT), N-Monochloro-2,2-Dimethyltaurine (NVC-612) and N,N-Dichloro-2,2-Dimethyltaurine (NVC-422) against Influenza Viruses:

Professor Markus Nagl, MD et al. evaluated the virucidal activity of NCT, NVC-612 and NVC-422 on three separate strains of influenza H1N1 also known as Swine Flu, (H1N1 Singapore, H1N1 California, and H1N1 Apr-8-38). The researchers determined that all three compounds exhibited a dose-dependent inhibition of H1N1 viral infectivity in a cell culture model.  Further investigation into this antiviral activity and its potential therapeutic utility is underway at NovaBay and with its European collaborators at the Medical University of Innsbruck in Austria.

http://www.novabaypharma.com/media/Aganocide_effective_against_h1n1.shtml

NVC-422: Towards Developing Preclinical Infected Tissue Models:

Dr. Dmitri Debabov et al. reported on two infected tissue models in human dermal and ocular epithelial cells. These models mimic the human infected tissue environment caused by P. aeruginosa and S. aureus. These models help to demonstrate the effect of an antimicrobial compound in a proprietary formulation regarding its activity and safety. NovaBay's lead Aganocide, NVC-422 demonstrated good antimicrobial killing with no safety issues in these infected tissue models. Furthermore, these results reflect what has been observed in NovaBay's human clinical trials.

Source :  NovaBay Pharmaceuticals, Inc.
Source:

http://www.novabaypharma.com/media/Novel_infected_tissue_model_for_evaluation_antimicrobial_compounds.shtml

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New study identifies novel compound as promising pan-coronavirus drug candidate